Zyner­ba cites 'triple­demic' for PhI­II de­lay of a cannabi­noid drug that's failed mul­ti­ple times

Zyner­ba Phar­ma­ceu­ti­cals’ cannabi­noid drug has flamed out mul­ti­ple times over the years, and the biotech’s lat­est at­tempt at prov­ing the gel’s ef­fi­ca­cy is be­ing ham­pered by what’s been re­ferred to as the “triple­dem­ic.”

The Penn­syl­va­nia biotech cit­ed the rise in RSV, in­fluen­za and Covid-19 cas­es as the rea­son for why its Phase III tri­al will no longer read out in the sec­ond half of 2023. The time­line has been pushed to the first half of 2024, Zyner­ba said Wednes­day morn­ing. That al­so means a sec­ond Phase III in an­oth­er in­di­ca­tion is be­ing pushed back as well.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER